



PTO/SB/08A (02-03)

Approved for use through 04/30/2003. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/626,229
		Filing Date	July 24, 2003
		First Named Inventor	Reubi, Jean-Claude
		Art Unit	1653
		Examiner Name	Not yet known
Sheet	1	of	1
		Attorney Docket Number	717816.23

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number- Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AEP	A1	US-5,620,675	04-15-1997	McBride, et al.	
		US-5,601,800	02-11-1997	Katti, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T ⁶

Examiner Initials*	Cite No. ⁷	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁸
AEP	B1	SLANINOVA, J. ET AL., [¹²⁵ I] SNF 8702: A Selective Radioligand for CCK _B Receptors, Peptides, Vol. 16, No. 2, pp 221-224, 1995	
	B2	SETHI, T. ET AL., Gastrin Stimulates Ca ²⁺ Mobilization and Clonal Growth in Small Cell Lung Cancer Cells, Cancer Research , November 1, 1992, Volume 52, pp. 6031-6035 (abstract only)	
	B3	EDMUNDSON, A.B. ET AL., Binding of N-Formylated Chemotactic Peptides in Crystals; Molecular Immunology, April 1985, Volume 22, pp. 463-475 (abstract only)	
	B4	RICHARDS, A.D. ET AL., Sensitive, Soluble Chromogenic Substrates for HIV-1 Proteinase, Journal of Biological Chemistry, 1990, Volume 265, pp. 7733-7736 (abstract only)	
	B5	MORODER, L. ET AL., Hoppe-Seylers Zeitschrift fur Physiologische Chemie, July 1981, Volume 362, pp. 929-942 (abstract only)	

Examiner Signature		Date Considered	03/13/06
--------------------	--	-----------------	----------

6

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.


Include copy of this from with next communication to applicant.

¹ Applicant's unique citation designation number (optional).² Applicant is to place a check mark here if English Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gather, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

Complete if Known	
Application Number	10/626,229
Filing Date	July 24, 2003
First Named Inventor	Reubi, Jean-Claude
Art Unit	1653
Examiner Name	Holleran, Anne L.
Attorney Docket Number	717816.23

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number- Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code Number- Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T I
AIP	A1	DE JONG, MARION, et al.; Preclinical and Initial Clinical Evaluation of ¹¹¹ In-Labeled Nonsulfated CCK ₈ Analog: A Peptide for CCK-B Receptor-Targeted Scintigraphy and Radionuclide Therapy; The Journal Of Nuclear Medicine; 1999; pp. 2081 – 2087; Vol. 40, No. 12, Society of Nuclear Medicine, Published in Reston, Virginia, U.S.A.	

Examiner Signature		Date Considered	03/13/06
--------------------	--	-----------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² Applicant is to place a check mark here if English Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gather, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/626,229
Sheet	1	of	1	Filing Date	July 24, 2003
				First Named Inventor	Reubi, Jean-Claude
				Art Unit	1653
				Examiner Name	Not yet known
				Attorney Docket Number	717816.23

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number- Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US-				
	US-				

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

Examiner Initials*	Cite No. ⁷	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁸
AJP	A1	KWEKKEBOOM, ET AL., Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma, European Journal of Nuclear Medicine, 2000, Vol. 27, pp. 1312-1317	✓
	A2	REUBI, ET AL., Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo, European Journal of Nuclear Medicine, 1998, Vol. 25, pp. 481-490	✓
	A3	MATSUMORI, ET AL. Cholecystokinin-B/gastrin receptor: a novel molecular probe for human small cell lung cancer, Cancer Research, Vol 55, 1995 Issue 2, pp. 276-279	✓
	A4	REUBI, ET AL. , Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in Human Tumors, Cancer Research, Vol 57, Issue 7, pp. 1377-1386	
	A5	MAILLEUX, ET AL., Cholecystokinin Receptors of A Type in the Human Dorsal Medulla-Oblongata and Meningiomas, and of B Type in Small Cell Lung Carcinomas, Neuroscience Letters, Volume 117, Issue 3, 18 September 1990, Pages 243-247.	✓

Examiner Signature		Date Considered	03/16/06
--------------------	--	-----------------	----------

6

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² Applicant is to place a check mark here if English Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gather, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.